7
|
Fehér Á, Tóth VE, Al-Khrasani M, Balogh M, Lázár B, Helyes Z, Gyires K, Zádori ZS. Analysing the effect of I 1 imidazoline receptor ligands on DSS-induced acute colitis in mice. Inflammopharmacology 2016; 25:107-118. [PMID: 27873165 DOI: 10.1007/s10787-016-0299-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2016] [Accepted: 11/13/2016] [Indexed: 12/28/2022]
Abstract
Imidazoline receptors (IRs) have been recognized as promising targets in the treatment of numerous diseases; and moxonidine and rilmenidine, agonists of I1-IRs, are widely used as antihypertensive agents. Some evidence suggests that IR ligands may induce anti-inflammatory effects acting on I1-IRs or other molecular targets, which could be beneficial in patients with inflammatory bowel disease (IBD). On the other hand, several IR ligands may stimulate also alpha2-adrenoceptors, which were earlier shown to inhibit, but in more recent studies to rather aggravate colitis. Hence, this study aimed to analyse for the first time the effect of various I1-IR ligands on intestinal inflammation. Colitis was induced in C57BL/6 mice by adding dextran sulphate sodium (DSS) to the drinking water for 7 days. Mice were treated daily with different IR ligands: moxonidine and rilmenidine (I1-IR agonists), AGN 192403 (highly selective I1-IR ligand, putative antagonist), efaroxan (I1-IR antagonist), as well as with the endogenous IR agonists agmatine and harmane. It was found that moxonidine and rilmenidine at clinically relevant doses, similarly to the other IR ligands, do not have a significant impact on the macroscopic and histological signs of DSS-evoked inflammation. Likewise, colonic myeloperoxidase and serum interleukin-6 levels remained unchanged in response to these agents. Thus, our study demonstrates that imidazoline ligands do not influence significantly the severity of DSS-colitis in mice and suggest that they probably neither affect the course of IBD in humans. However, the translational value of these findings needs to be verified with other experimental colitis models and human studies.
Collapse
Affiliation(s)
- Ágnes Fehér
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, Budapest, 1089, Hungary
| | - Viktória E Tóth
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, Budapest, 1089, Hungary
| | - Mahmoud Al-Khrasani
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, Budapest, 1089, Hungary
| | - Mihály Balogh
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, Budapest, 1089, Hungary
| | - Bernadette Lázár
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, Budapest, 1089, Hungary
| | - Zsuzsanna Helyes
- Department of Pharmacology and Pharmacotherapy, Szentagothai Research Centre and MTA-NAP B Chronic Pain Research Group, University of Pécs, Pécs, Hungary
| | - Klára Gyires
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, Budapest, 1089, Hungary
| | - Zoltán S Zádori
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, Budapest, 1089, Hungary.
| |
Collapse
|
8
|
Zádori ZS, Tóth VE, Fehér Á, Al-Khrasani M, Puskár Z, Kozsurek M, Timár J, Tábi T, Helyes Z, Hein L, Holzer P, Gyires K. Inhibition of α2A-Adrenoceptors Ameliorates Dextran Sulfate Sodium-Induced Acute Intestinal Inflammation in Mice. J Pharmacol Exp Ther 2016; 358:483-91. [PMID: 27418171 DOI: 10.1124/jpet.116.235101] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2016] [Accepted: 07/08/2016] [Indexed: 12/19/2022] Open
Abstract
It has been hypothesized that α2-adrenoceptors (α2-ARs) may be involved in the pathomechanism of colitis; however, the results are conflicting because both aggravation and amelioration of colonic inflammation have been described in response to α2-AR agonists. Therefore, we aimed to analyze the role of α2-ARs in acute murine colitis. The experiments were carried out in wild-type, α2A-, α2B-, and α2C-AR knockout (KO) C57BL/6 mice. Colitis was induced by dextran sulfate sodium (DSS, 2%); alpha2-AR ligands were injected i.p. The severity of colitis was determined both macroscopically and histologically. Colonic myeloperoxidase (MPO) and cytokine levels were measured by enzyme-linked immunosorbent assay and proteome profiler array, respectively. The nonselective α2-AR agonist clonidine induced a modest aggravation of DSS-induced colitis. It accelerated the disease development and markedly enhanced the weight loss of animals, but did not influence the colon shortening, tissue MPO levels, or histologic score. Clonidine induced similar changes in α2B- and α2C-AR KO mice, whereas it failed to affect the disease activity index scores and caused only minor weight loss in α2A-AR KO animals. In contrast, selective inhibition of α2A-ARs by BRL 44408 significantly delayed the development of colitis; reduced the colonic levels of MPO and chemokine (C-C motif) ligand 3, chemokine (C-X-C motif) ligand 2 (CXCL2), CXCL13, and granulocyte-colony stimulating factor; and elevated that of tissue inhibitor of metalloproteinases-1. In this work, we report that activation of α2-ARs aggravates murine colitis, an effect mediated by the α2A-AR subtype, and selective inhibition of these receptors reduces the severity of gut inflammation.
Collapse
Affiliation(s)
- Zoltán S Zádori
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine (Z.S.Z., V.E.T., Á.F., M.A.-K., J.T., K.G.), Department of Anatomy, Histology, and Embryology, János Szentágothai Laboratory (Z.P., M.K.), and Department of Pharmacodynamics (T.T.), Semmelweis University, Budapest, Hungary; Department of Pharmacology and Pharmacotherapy, Szentagothai Research Centre and MTA-NAP B Chronic Pain Research Group, University of Pécs, Pécs, Hungary (Z.H.); Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine and BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany (L.H.); and Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria (P.H.)
| | - Viktória E Tóth
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine (Z.S.Z., V.E.T., Á.F., M.A.-K., J.T., K.G.), Department of Anatomy, Histology, and Embryology, János Szentágothai Laboratory (Z.P., M.K.), and Department of Pharmacodynamics (T.T.), Semmelweis University, Budapest, Hungary; Department of Pharmacology and Pharmacotherapy, Szentagothai Research Centre and MTA-NAP B Chronic Pain Research Group, University of Pécs, Pécs, Hungary (Z.H.); Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine and BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany (L.H.); and Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria (P.H.)
| | - Ágnes Fehér
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine (Z.S.Z., V.E.T., Á.F., M.A.-K., J.T., K.G.), Department of Anatomy, Histology, and Embryology, János Szentágothai Laboratory (Z.P., M.K.), and Department of Pharmacodynamics (T.T.), Semmelweis University, Budapest, Hungary; Department of Pharmacology and Pharmacotherapy, Szentagothai Research Centre and MTA-NAP B Chronic Pain Research Group, University of Pécs, Pécs, Hungary (Z.H.); Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine and BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany (L.H.); and Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria (P.H.)
| | - Mahmoud Al-Khrasani
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine (Z.S.Z., V.E.T., Á.F., M.A.-K., J.T., K.G.), Department of Anatomy, Histology, and Embryology, János Szentágothai Laboratory (Z.P., M.K.), and Department of Pharmacodynamics (T.T.), Semmelweis University, Budapest, Hungary; Department of Pharmacology and Pharmacotherapy, Szentagothai Research Centre and MTA-NAP B Chronic Pain Research Group, University of Pécs, Pécs, Hungary (Z.H.); Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine and BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany (L.H.); and Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria (P.H.)
| | - Zita Puskár
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine (Z.S.Z., V.E.T., Á.F., M.A.-K., J.T., K.G.), Department of Anatomy, Histology, and Embryology, János Szentágothai Laboratory (Z.P., M.K.), and Department of Pharmacodynamics (T.T.), Semmelweis University, Budapest, Hungary; Department of Pharmacology and Pharmacotherapy, Szentagothai Research Centre and MTA-NAP B Chronic Pain Research Group, University of Pécs, Pécs, Hungary (Z.H.); Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine and BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany (L.H.); and Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria (P.H.)
| | - Márk Kozsurek
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine (Z.S.Z., V.E.T., Á.F., M.A.-K., J.T., K.G.), Department of Anatomy, Histology, and Embryology, János Szentágothai Laboratory (Z.P., M.K.), and Department of Pharmacodynamics (T.T.), Semmelweis University, Budapest, Hungary; Department of Pharmacology and Pharmacotherapy, Szentagothai Research Centre and MTA-NAP B Chronic Pain Research Group, University of Pécs, Pécs, Hungary (Z.H.); Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine and BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany (L.H.); and Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria (P.H.)
| | - Júlia Timár
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine (Z.S.Z., V.E.T., Á.F., M.A.-K., J.T., K.G.), Department of Anatomy, Histology, and Embryology, János Szentágothai Laboratory (Z.P., M.K.), and Department of Pharmacodynamics (T.T.), Semmelweis University, Budapest, Hungary; Department of Pharmacology and Pharmacotherapy, Szentagothai Research Centre and MTA-NAP B Chronic Pain Research Group, University of Pécs, Pécs, Hungary (Z.H.); Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine and BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany (L.H.); and Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria (P.H.)
| | - Tamás Tábi
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine (Z.S.Z., V.E.T., Á.F., M.A.-K., J.T., K.G.), Department of Anatomy, Histology, and Embryology, János Szentágothai Laboratory (Z.P., M.K.), and Department of Pharmacodynamics (T.T.), Semmelweis University, Budapest, Hungary; Department of Pharmacology and Pharmacotherapy, Szentagothai Research Centre and MTA-NAP B Chronic Pain Research Group, University of Pécs, Pécs, Hungary (Z.H.); Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine and BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany (L.H.); and Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria (P.H.)
| | - Zsuzsanna Helyes
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine (Z.S.Z., V.E.T., Á.F., M.A.-K., J.T., K.G.), Department of Anatomy, Histology, and Embryology, János Szentágothai Laboratory (Z.P., M.K.), and Department of Pharmacodynamics (T.T.), Semmelweis University, Budapest, Hungary; Department of Pharmacology and Pharmacotherapy, Szentagothai Research Centre and MTA-NAP B Chronic Pain Research Group, University of Pécs, Pécs, Hungary (Z.H.); Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine and BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany (L.H.); and Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria (P.H.)
| | - Lutz Hein
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine (Z.S.Z., V.E.T., Á.F., M.A.-K., J.T., K.G.), Department of Anatomy, Histology, and Embryology, János Szentágothai Laboratory (Z.P., M.K.), and Department of Pharmacodynamics (T.T.), Semmelweis University, Budapest, Hungary; Department of Pharmacology and Pharmacotherapy, Szentagothai Research Centre and MTA-NAP B Chronic Pain Research Group, University of Pécs, Pécs, Hungary (Z.H.); Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine and BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany (L.H.); and Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria (P.H.)
| | - Peter Holzer
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine (Z.S.Z., V.E.T., Á.F., M.A.-K., J.T., K.G.), Department of Anatomy, Histology, and Embryology, János Szentágothai Laboratory (Z.P., M.K.), and Department of Pharmacodynamics (T.T.), Semmelweis University, Budapest, Hungary; Department of Pharmacology and Pharmacotherapy, Szentagothai Research Centre and MTA-NAP B Chronic Pain Research Group, University of Pécs, Pécs, Hungary (Z.H.); Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine and BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany (L.H.); and Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria (P.H.)
| | - Klára Gyires
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine (Z.S.Z., V.E.T., Á.F., M.A.-K., J.T., K.G.), Department of Anatomy, Histology, and Embryology, János Szentágothai Laboratory (Z.P., M.K.), and Department of Pharmacodynamics (T.T.), Semmelweis University, Budapest, Hungary; Department of Pharmacology and Pharmacotherapy, Szentagothai Research Centre and MTA-NAP B Chronic Pain Research Group, University of Pécs, Pécs, Hungary (Z.H.); Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine and BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany (L.H.); and Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria (P.H.)
| |
Collapse
|